Skip to Content

IMGN529 Approval Status

FDA Approved: No
Brand name: IMGN529
Company: ImmunoGen, Inc.
Treatment for: Non-Hodgkin's Lymphoma

IMGN529 is a CD37-targeting Antibody-Drug Conjugate (ADC) in development for the treatment of non-Hodgkin's Lymphoma and other B-cell malignancies.

Development Status and FDA Approval Process for IMGN529

DateArticle
Dec  6, 2014ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition
Sep 23, 2011ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide